Danish Headache Center
rigshospitalet.dkTotal trials
129
Active
13
Phase 3
2
Total enrollment
8,098
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Botox 200 UNT | — | — | — | — | — | 1 | |
| Adrenomedullin | — | — | — | — | — | 2 | |
| Amylin | — | — | — | — | — | 2 | |
| Substance P | — | — | — | — | — | 2 | |
| Pituitary Adenylate Cyclase Activating Polypeptide-38 | — | — | — | — | — | 2 | |
| Calcitonin-gene related peptide | — | — | — | — | — | 2 |
Next readouts
- 2025-12-31
- 2026-03-01
- 2026-05-01
- 2026-06-01
- 2026-12-01
- 2027-03-10
- 2028-05-01
- 2028-10-30
- 2028-12
Top conditions
- Migraine36
- Headache29
- Migraine Without Aura18
- Headache, Migraine11
- Post-Traumatic Headache9
- Migraine With Aura8
- Headache Disorders8
- Healthy7
Frequently asked questions about Danish Headache Center
- How many clinical trials does Danish Headache Center have on ClinicalTrials.gov?
- Danish Headache Center is listed as the lead sponsor on 129 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Danish Headache Center's trials are in Phase 3?
- 2 of Danish Headache Center's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Danish Headache Center focus on?
- Danish Headache Center's most-studied conditions on ClinicalTrials.gov are Migraine, Headache, Migraine Without Aura, Headache, Migraine, Post-Traumatic Headache.
- When are Danish Headache Center's next clinical trial readouts?
- Danish Headache Center has 9 upcoming primary-completion readouts tracked here; the soonest is “Effects of Substance P on Headache Induction in Healthy Individuals”, expected around 2025-12-31.